Abe, Jiro
Vujic, Ana
Prag, Hiran A.
Murphy, Michael P.
Krieg, Thomas http://orcid.org/0000-0002-5192-580X
Funding for this research was provided by:
British Heart Foundation (PG/20/10025)
Medical Research Council (MC_UU_00015/3)
Wellcome Trust (220257/Z/20/Z)
Article History
Received: 5 January 2024
Revised: 4 June 2024
Accepted: 5 June 2024
First Online: 12 June 2024
Declarations
:
: H.A.P., M.P.M., and T.K. have pending patents on targeting succinate metabolism in ischemia/reperfusion injury. M.P.M. and T.K. are directors of Camoxis Therapeutics Ltd.